A bipartisan group of six senators introduced legislation to reform the U.S. 340B drug program, challenging HHS’s contested rebate push. The bill proposes locking in hospitals’ use of contract pharmacies and adding transparency and compliance rules for program oversight. The proposal also targets HHS’s rebate pilot, which it would replace within a year with a national data clearinghouse designed to reduce duplicate discounts. The move reflects heightened scrutiny of how 340B program rules affect access, pricing, and reimbursement. For biotech manufacturers and hospital stakeholders, 340B remains a major driver of commercial dynamics, particularly for high-volume drug categories and specialty products.